$UNCY
Unicycive Therapeutics, Inc. Stock $uncy

$uncy Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000121390023024901 Filed on March 31, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$675.0K	$0.00	$951.0K
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$62.00K	$1.485M	$383.0K
YoY Change	-96.13%	6.76%	-86.78%
% of Gross Profit
Research & Development	$3.030M	$3.840M	$12.44M
YoY Change	56.75%	182.15%	104.54%
% of Gross Profit
Depreciation & Amortization	$2.000K	$2.000K	$428.0K
YoY Change	0.0%	100.0%	42700.0%
% of Gross Profit
Operating Expenses	$4.877M	$5.325M	$19.00M
YoY Change	37.89%	93.5%	111.69%
Operating Profit	-$4.202M		-$18.05M
YoY Change			101.09%
Interest Expense	$12.00K	-$3.000K	$6.000K
YoY Change			-100.96%
% of Operating Profit
Other Income/Expense, Net	-$10.38M	$0.00	-$6.000K
YoY Change			-98.61%
Pretax Income	-$14.58M	-$5.328M	-$18.06M
YoY Change	312.07%	93.6%	80.27%
Income Tax
% Of Pretax Income
Net Earnings	-$14.58M	-$5.328M	-$18.06M
YoY Change	312.07%	93.6%	80.27%
Net Earnings / Revenue	-2159.26%		-1898.84%
Basic Earnings Per Share	-$0.97		-$1.20
Diluted Earnings Per Share	-$0.97	-$0.35	-$1.20
COMMON SHARES
Basic Shares Outstanding	15.23M shares	15.09M shares	15.06M shares
Diluted Shares Outstanding	15.23M shares		15.06M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$24.33M	$455.0K	$455.0K
YoY Change	78.65%	-97.26%	-97.26%
Cash & Equivalents	$24.33M	$455.0K
Short-Term Investments
Other Short-Term Assets	$1.852M	$2.189M	$2.189M
YoY Change	0.43%	19.49%	19.49%
Inventory	$1.852M	$2.189M
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$26.18M	$2.644M	$2.644M
YoY Change	69.32%	-85.64%	-85.64%
LONG-TERM ASSETS
Property, Plant & Equipment	$21.00K	$22.00K	$174.0K
YoY Change	-92.91%	-21.43%	-47.75%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$1.018M	$174.0K	$174.0K
YoY Change	243.92%	-47.75%	-47.75%
TOTAL ASSETS
Total Short-Term Assets	$26.18M	$2.644M	$2.644M
Total Long-Term Assets	$1.018M	$174.0K	$174.0K
Total Assets	$27.20M	$2.818M	$2.818M
YoY Change	72.6%	-84.97%	-84.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$790.0K	$892.0K	$892.0K
YoY Change	34.13%	20.22%	20.22%
Accrued Expenses	$1.698M	$2.237M	$2.392M
YoY Change	-6.34%	84.57%	75.5%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$15.97M	$3.284M	$3.284M
YoY Change	564.86%	56.01%	56.01%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$715.0K	$0.00	$0.00
YoY Change	527.19%	-100.0%	-100.0%
Total Long-Term Liabilities	$715.0K	$0.00	$0.00
YoY Change	527.19%	-100.0%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$15.97M	$3.284M	$3.284M
Total Long-Term Liabilities	$715.0K	$0.00	$0.00
Total Liabilities	$16.69M	$3.284M	$3.284M
YoY Change	563.16%	45.31%	45.31%
SHAREHOLDERS EQUITY
Retained Earnings	-$48.57M	-$34.00M
YoY Change		113.29%
Common Stock	$15.00K	$15.00K
YoY Change		0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$15.08M	-$466.0K	-$466.0K
YoY Change
Total Liabilities & Shareholders Equity	$27.20M	$2.818M	$2.818M
YoY Change	72.6%	-84.97%	-84.97%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$14.58M	-$5.328M	-$18.06M
YoY Change	312.07%	93.6%	80.27%
Depreciation, Depletion And Amortization	$2.000K	$2.000K	$428.0K
YoY Change	0.0%	100.0%	42700.0%
Cash From Operating Activities	-$3.920M	-$6.084M	-$15.65M
YoY Change	32.57%	333.64%	171.39%
INVESTING ACTIVITIES
Capital Expenditures		$0.00	$2.000K
YoY Change		-100.0%	-106.9%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities		$0.00	-$2.000K
YoY Change		-100.0%	-93.1%
FINANCING ACTIVITIES
Cash Dividend Paid	$200.0K
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$27.80M	-471.0K	-$471.0K
YoY Change			-102.11%
NET CHANGE
Cash From Operating Activities	-$3.920M	-6.084M	-$15.65M
Cash From Investing Activities		0.000	-$2.000K
Cash From Financing Activities	$27.80M	-471.0K	-$471.0K
Net Change In Cash	$23.88M	-6.555M	-$16.12M
YoY Change		357.75%	-197.26%
FREE CASH FLOW
Cash From Operating Activities	-$3.920M	-$6.084M	-$15.65M
Capital Expenditures		$0.00	$2.000K
Free Cash Flow	-$3.920M	-$6.084M	-$15.65M
YoY Change	32.66%	342.79%	172.8%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-40582
CY2022	dei	Entity Registrant Name EntityRegistrantName	UNICYCIVE THERAPEUTICS, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	81-3638692
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	4300 El Camino Real
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 210
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Los Altos
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94022
CY2022	dei	City Area Code CityAreaCode	(650)
CY2022	dei	Local Phone Number LocalPhoneNumber	351-4495
CY2022	dei	Security12b Title Security12bTitle	Common stock, par value $0.001 per share
CY2022	dei	Trading Symbol TradingSymbol	UNCY
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	12486933	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	15233836	shares
CY2022	dei	Auditor Firm AuditorFirmId	199
CY2022	dei	Auditor Name AuditorName	Mayer Hoffman McCann P.C.
CY2022	dei	Auditor Location AuditorLocation	San Diego, California
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16579000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	455000	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1832000	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	2189000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	18411000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	2644000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	305000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	152000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	28000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22000	usd
CY2021Q4	us-gaap	Assets Assets	18744000	usd
CY2022Q4	us-gaap	Assets Assets	2818000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	742000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	892000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1212000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2237000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	151000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	155000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2105000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3284000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	155000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	2260000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	3284000	usd
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14996534	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14996534	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15231655	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15231655	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	15000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	15000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	32408000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	33516000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-15939000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-33997000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	16484000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-466000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	18744000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2818000	usd
CY2022	us-gaap	Revenues Revenues	951000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6080000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12436000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2897000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6567000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	8977000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	19003000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-8977000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-18052000	usd
CY2021	us-gaap	Interest Expense InterestExpense	628000	usd
CY2022	us-gaap	Interest Expense InterestExpense	6000	usd
CY2021	uncy	Loss On Debt Conversion LossOnDebtConversion	-431000	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	19000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1040000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-10017000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18058000	usd
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.86
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.2
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11675750	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15057049	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-2671000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-10017000	usd
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	22271000	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	3685000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	59000	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	2191000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	966000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	16484000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18058000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	11000	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	21000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	29000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1047000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-466000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-10017000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18058000	usd
CY2021	us-gaap	Depreciation Depreciation	1000	usd
CY2022	us-gaap	Depreciation Depreciation	7000	usd
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	2191000	usd
CY2022	us-gaap	Other Noncash Expense OtherNoncashExpense	21000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	966000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1047000	usd
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	488000	usd
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	12000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	154000	usd
CY2021	us-gaap	Paid In Kind Interest PaidInKindInterest	139000	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	19000	usd
CY2021	uncy	Deferred Compensation To Ceo DeferredCompensationToCEO	146000	usd
CY2021	uncy	Loss On Debt Conversion LossOnDebtConversion	-431000	usd
CY2021	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	1325000	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-62000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1241000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1267000	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-12000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-151000	usd
CY2021	uncy	Related Party Service Fee Payable RelatedPartyServiceFeePayable	9000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5767000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15651000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	29000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-29000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2000	usd
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	22271000	usd
CY2022	uncy	Issuance Of Common Stock For Cash Net Of Issuance Costs IssuanceOfCommonStockForCashNetOfIssuanceCosts	-11000	usd
CY2021	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	248000	usd
CY2021	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	1098000	usd
CY2021	us-gaap	Repayments Of Other Short Term Debt RepaymentsOfOtherShortTermDebt	1361000	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	482000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	119000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	22375000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-471000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	16579000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-16124000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16579000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16579000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	455000	usd
CY2021	uncy	Deferred Preclinical Charges Included In Prepaid Expenses And Other Current Assets DeferredPreclinicalChargesIncludedInPrepaidExpensesAndOtherCurrentAssets	503000	usd
CY2022	uncy	Deferred Preclinical Charges Included In Prepaid Expenses And Other Current Assets DeferredPreclinicalChargesIncludedInPrepaidExpensesAndOtherCurrentAssets	420000	usd
CY2022	uncy	Deferred Insurance Charges Included In Prepaid Expenses And Other Current Assets DeferredInsuranceChargesIncludedInPrepaidExpensesAndOtherCurrentAssets	240000	usd
CY2022	uncy	Licensing Revenue LicensingRevenue	1000000	usd
CY2021Q4	uncy	Accmulated Deficit AccmulatedDeficit	15900000	usd
CY2022Q4	uncy	Accmulated Deficit AccmulatedDeficit	34000000	usd
CY2023Q1	uncy	Purchase Agreement PurchaseAgreement	130000000	usd
CY2023Q1	uncy	Gross Proceeds GrossProceeds	30000000	usd
CY2022	uncy	Financial Term FinancialTerm	P1Y
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the periods presented. Management believes that these estimates and assumptions are reasonable; however, actual results may differ and could have a material effect on future results of operations and financial position. Significant items subject to such estimates and assumptions include stock-based compensation. Actual results may materially differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p>
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Concentration of Credit Risk</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash. All of the Company’s cash was deposited in one account at a financial institution during 2021 and 2022, and the account balance may at times exceed federally insured limits. The cash and cash equivalents we use to satisfy our working capital and operating expense needs are currently held in accounts at various financial institutions. Cash and cash equivalents could be adversely impacted, including the loss of uninsured deposits and other uninsured financial assets, if one or more of the financial institutions in which the Company holds its cash or cash equivalents fails or is subject to other adverse conditions in the financial or credit markets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p>
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.20
CY2022	uncy	Income Tax Largest Amount IncomeTaxLargestAmount	0.50	pure
CY2022	uncy	Significant Agreements Policies SignificantAgreementsPolicies	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>3. Significant Agreements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With regards to manufacturing, testing and potential commercial supply of Renazorb, the Company has entered into an agreement with Shilpa Medicare Ltd based in India. According to the terms of the agreement Unicycive will pay the vendor $2 million in the first calendar year when the net revenue reaches $10 million from sales of Renazorb following its approval by the FDA and commercial supply of the product by the vendor (First Payment). Thereafter, the Company will pay $2 million per year for four consecutive years, after the first year’s payment, for the total payments of $10 million, provided all commercial supplies are continued to be manufactured and supplied by the vendor. Unicycive is not obligated to make any payments to the vendor until FDA approval of the product is obtained and commercial revenue is generated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2017, the Company entered into an exclusive license agreement with Sphaera, a stockholder, for the rights to further develop the drug candidate, UNI 494, for commercialization. No payments were made upon execution of the agreement but rather payments for $50,000 will be due commencing with the initiation by the Company of a second clinical trial and $50,000 on completion of such trial. At the time the FDA accepts a NDA application submitted by the Company for the product, the Company will pay Sphaera $1.65 million. Upon commercialization and sale of the drug product, royalty payments will also be payable quarterly to Sphaera equal to 2% of net sales on the preceding quarter.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2018, the Company entered into an Assignment and Asset Purchase Agreement with Spectrum Pharmaceuticals, Inc. (“Spectrum Agreement”) pursuant to which the Company purchased certain assets from Spectrum, including Spectrum’s right, title, interest in and intellectual property related to Renazorb RZB 012, also known as RENALAN™ (“Renalan”) and RZB 014, also known as SPI 014 (“SPI” and together with Renalan, the “Compounds”), to further develop and commercialize Renazorb and related compounds. In partial consideration for the Spectrum Agreement, the Company issued 313,663 shares of common stock to Spectrum valued at approximately $4,000 which represented four percent of the Company on a fully-diluted basis at the date of the execution of the Spectrum Agreement. The Spectrum Agreement has an anti-dilution provision, which provides that Spectrum maintain its ownership interest in the Company at 4% of the Company’s shares on a fully-diluted basis. Fully-diluted shares of common stock for purposes of the Renazorb Purchase Agreement assumes conversion of any security convertible into or exchangeable or exercisable for common stock or any combination thereof, including any common stock reserved for issuance under a stock option plan, restricted stock plan, or other equity incentive plan approved by the Board of Directors of the Company immediately following the issuance of additional shares of the Company’s common stock (but prior to the issuance of any additional shares of common stock to Spectrum). Spectrum’s ownership shall not be subject to dilution until the earlier of thirty-six months from the first date the Company’s stock trades on a public market, or the date upon which the Company attains a public market capitalization of at least $50 million. On July 13, 2021, the Company’s initial public offering resulted in a public market capitalization of at least $50 million, and as a result the Company was required to issue 438,374 anti-dilution shares of common stock. This issuance represented the final anti-dilution calculation required under the Spectrum Agreement, and no further anti-dilution shares will be issued. The Company calculated the fair value of the shares and recognized $2.2 million to research and development expenses as cost to issue those shares during the third quarter of 2021. In the event an NDA filing for Renazorb is accepted by the FDA, the Company will be required to pay $0.2 million to Altair Nanomaterials, Inc., (“Altair”) in accordance with the Spectrum Agreement. In addition, in the event FDA approval for Renazorb is received, the Company will be required to pay $4.5 million to Altair. The Company is also required to pay Spectrum 40% of all of the Company’s sublicense income for any sublicense granted to certain sublicensees during the first 12 months after the Closing Date (as that term is defined in the Renazorb Purchase Agreement) and 20% of all other sublicense income. The Company’s payment obligations to Spectrum will expire on the twentieth (20<sup>th</sup>) anniversary of the Closing Date of the Renazorb Purchase Agreement. In August 2022, the Company received an upfront payment of approximately $1.0 million as a result of a sublicense development agreement with Lee’s Pharmaceutical (HK) Limited. The payment represents sublicense income as described in the Spectrum Agreement, and 20% of the amount received has been accrued as an R&D expense in the accompanying statements of operations for the year ended December 31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 19, 2021, the Company entered into an agreement with Syneos Health LLC (“Syneos”) pursuant to which Syneos will provide preclinical research and analysis services related to the development of UNI-494. The initial budget for the study, which includes clinical pharmacology, translational sciences, and bioanalytical services, was approximately $2.3 million. Related payments totaling approximately $1.8 million have been paid to Syneos as of December 31, 2022, and approximately $0.2 million has been recorded as accounts payable or accrued expense in the accompanying balance sheet as of December 31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 6, 2022, the Company entered into a Master Services Agreement with Quotient Sciences Limited (“Quotient”), a UK based company that provides drug development and analysis services, for the purpose of performing clinical research in support of UNI-494. The initial budget for the study is approximately $3.7 million, and subsequent revisions reduced the overall budget to $2.6 million. Related payments totaling approximately $1.5 million have been paid to Quotient as of December 31, 2022, approximately $0.9 million of related expense has been recorded, and approximately $1.0 million has been recorded as prepaid expense in the accompanying balance sheet as of December 31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 9, 2022, the Company entered into a Master Services Agreement with CBCC Global Research Inc. (“CBCC”), a California based company that provides clinical trial and related services, for the purpose of performing clinical research in support of Renazorb. The budget for the initial study was approximately $1.4 million. Payments relating to the initial agreement totaling approximately $0.4 million have been paid to CBCC as of December 31, 2022, and approximately $0.4 million of related expense has been recorded. In September 2022, a statement of work revised the remaining services budget to approximately $0.1 million.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 29, 2022, the Company entered into an Agreement with Inotiv, an Indiana based company that provides preclinical trial and related services, for the purpose of performing research in support of Renazorb. The budget for the services is approximately $1.0 million. Approximately $0.7 million has been paid to Inotiv as of December 31, 2022 and approximately $0.4 million has been recorded as prepaid expense in the accompanying balance sheet as of December 31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 14, 2022, the Company entered into a license agreement with Lee’s Pharmaceutical (HK) Limited (see Note 4). Under the terms of the agreement, Lee’s Pharmaceutical will be responsible for development, registration filing and approval for Renazorb in China, Hong Kong, and certain other Asian markets. In addition, Lee’s Pharmaceutical will have sole responsibility for the importation of the drug product from the Company and for the costs of commercialization of Renazorb in the licensed territories. The Company has received an upfront payment of $1.0 million, expects to receive up to $1.0 million in milestone payments upon product launch in China and will be eligible for tiered royalties of between 7% and 10% upon achievement of prespecified regulatory and commercial achievements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 27, 2022, the Company entered into an Agreement with Celerion, a Nebraska based company that provides clinical trial and related services, for the purpose of performing research in support of Renazorb. The budget for the services is approximately $2.7 million, and approximately $2.7 million has been paid to Celerion as of December 31, 2022.</p>
CY2022	us-gaap	Debt Instrument Description DebtInstrumentDescription	According to the terms of the agreement Unicycive will pay the vendor $2 million in the first calendar year when the net revenue reaches $10 million from sales of Renazorb following its approval by the FDA and commercial supply of the product by the vendor (First Payment). Thereafter, the Company will pay $2 million per year for four consecutive years, after the first year’s payment, for the total payments of $10 million, provided all commercial supplies are continued to be manufactured and supplied by the vendor.
CY2017Q4	us-gaap	Broadcasters License Agreement Commitments Description BroadcastersLicenseAgreementCommitmentsDescription	No payments were made upon execution of the agreement but rather payments for $50,000 will be due commencing with the initiation by the Company of a second clinical trial and $50,000 on completion of such trial. At the time the FDA accepts a NDA application submitted by the Company for the product, the Company will pay Sphaera $1.65 million. Upon commercialization and sale of the drug product, royalty payments will also be payable quarterly to Sphaera equal to 2% of net sales on the preceding quarter.
CY2021Q3	us-gaap	Capitalization Longterm Debt And Equity CapitalizationLongtermDebtAndEquity	50000000	usd
CY2021Q3	us-gaap	Incremental Common Shares Attributable To Equity Forward Agreements IncrementalCommonSharesAttributableToEquityForwardAgreements	438374	shares
CY2022	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	2200000	usd
CY2022	uncy	Purchase Agreement Description PurchaseAgreementDescription	The Company is also required to pay Spectrum 40% of all of the Company’s sublicense income for any sublicense granted to certain sublicensees during the first 12 months after the Closing Date (as that term is defined in the Renazorb Purchase Agreement) and 20% of all other sublicense income. The Company’s payment obligations to Spectrum will expire on the twentieth (20th) anniversary of the Closing Date of the Renazorb Purchase Agreement.
CY2022Q3	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	1000000	usd
CY2022	uncy	Concentration Risk Percentage ConcentrationRiskPercentage	0.20	pure
CY2022Q1	uncy	Revisions Reduced The Overall Budget RevisionsReducedTheOverallBudget	2600000	usd
CY2022Q4	us-gaap	Prepaid Expense Other Noncurrent PrepaidExpenseOtherNoncurrent	1000000	usd
CY2022Q3	us-gaap	Discontinued Operation Amounts Of Material Contingent Liabilities Remaining DiscontinuedOperationAmountsOfMaterialContingentLiabilitiesRemaining	100000	usd
CY2022Q3	us-gaap	Defined Benefit Plan Funded Percentage DefinedBenefitPlanFundedPercentage	0.10	pure
CY2022	uncy	Budget For Services BudgetForServices	2700000	usd
CY2022Q3	uncy	Royalties Percentage RoyaltiesPercentage	0.07	pure
CY2022Q3	uncy	Regulatory And Commercial Achievements Percentage RegulatoryAndCommercialAchievementsPercentage	0.10	pure
CY2022	us-gaap-sup	Debt And Equity Securities And Foreign Currency Transaction Price Change Unrealized Gain Loss Operating Before Tax DebtAndEquitySecuritiesAndForeignCurrencyTransactionPriceChangeUnrealizedGainLossOperatingBeforeTax	1000000	usd
CY2022	us-gaap	Proceeds From License Fees Received ProceedsFromLicenseFeesReceived	1000000	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	821000	usd
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11675750	shares
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	476000	usd
CY2021Q4	uncy	Prepaid Preclinical Services PrepaidPreclinicalServices	885000	usd
CY2022Q4	uncy	Prepaid Preclinical Services PrepaidPreclinicalServices	1554000	usd
CY2021Q4	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	126000	usd
CY2022Q4	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	159000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	1832000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	2189000	usd
CY2021Q3	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2022	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	736773	shares
CY2022	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	184193	shares
CY2022Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2021Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	15000	usd
CY2022Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	15000	usd
CY2021Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	14000	usd
CY2022Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	14000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	29000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	29000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	28000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22000	usd
CY2021Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	713000	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	846000	usd
CY2021Q4	uncy	Credit Card Liability CreditCardLiability	29000	usd
CY2022Q4	uncy	Credit Card Liability CreditCardLiability	46000	usd
CY2021Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	742000	usd
CY2022Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	892000	usd
CY2021Q4	uncy	Accrued Labor Costs AccruedLaborCosts	691000	usd
CY2022Q4	uncy	Accrued Labor Costs AccruedLaborCosts	1487000	usd
CY2021Q4	uncy	Accrued Drug Development Costs AccruedDrugDevelopmentCosts	369000	usd
CY2022Q4	uncy	Accrued Drug Development Costs AccruedDrugDevelopmentCosts	228000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	152000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	522000	usd
CY2021Q4	us-gaap	Accrued Reclamation Costs Current AccruedReclamationCostsCurrent	1212000	usd
CY2022Q4	us-gaap	Accrued Reclamation Costs Current AccruedReclamationCostsCurrent	2237000	usd
CY2021Q3	us-gaap	Share Price SharePrice	5
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	154000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	152000	usd
CY2022	us-gaap	Operating Lease Payments Use OperatingLeasePaymentsUse	170000	usd
CY2021	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	14000	usd
CY2022	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	173000	usd
	uncy	Receives Gross Proceeds ReceivesGrossProceeds	500000	usd
CY2022	uncy	Conversion Price Percentage ConversionPricePercentage	0.70	pure
CY2021Q3	uncy	Conversion Shares Issued Percentage ConversionSharesIssuedPercentage	0.25	pure
CY2021	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	400000	usd
	uncy	Accrued Interest Percentage AccruedInterestPercentage	0.01	pure
CY2021	uncy	Received Advances From The Stockholder ReceivedAdvancesFromTheStockholder	248000	usd
CY2021	uncy	Repaid Amounts Owed To The Stockholder RepaidAmountsOwedToTheStockholder	1.4	usd
CY2017Q3	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	62181	shares
CY2017Q3	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.013
CY2022	us-gaap	Professional And Contract Services Expense ProfessionalAndContractServicesExpense	6000	usd
CY2021Q3	us-gaap	Noninterest Expense Investment Advisory Fees NoninterestExpenseInvestmentAdvisoryFees	150000	usd
CY2022	us-gaap	Noninterest Expense Investment Advisory Fees NoninterestExpenseInvestmentAdvisoryFees	100000	usd
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	4784193	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P4Y6M14D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	4784193	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P4Y6M14D
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	1302326	shares
CY2021Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	674176	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	389676	shares
CY2020Q2	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	348837	shares
CY2021Q1	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	1767442	shares
CY2020	us-gaap	Share Based Goods And Nonemployee Services Transaction Shares Approved For Issuance ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance	465116	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	17442	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1211068	shares
CY2021Q4	uncy	Weighted Average Exercise Price Options Outstanding Beginning WeightedAverageExercisePriceOptionsOutstandingBeginning	3.19
CY2022Q4	uncy	Weighted Average Remaining Contractual Term Outstanding WeightedAverageRemainingContractualTermOutstanding	P8Y7M28D
CY2021Q4	uncy	Aggregate Intrinsic Value Outstanding Beginningin Dollars AggregateIntrinsicValueOutstandingBeginninginDollars	321000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	324000	shares
CY2022	uncy	Share Based Weighted Average Exercise Price Options Options Exercised Share-basedWeightedAverageExercisePriceOptionsOptionsExercised	0.75	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	125547	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	3.05
CY2022	uncy	Number Of Shares Underlying Outstanding Options Options Exercised NumberOfSharesUnderlyingOutstandingOptionsOptionsExercised	66851	shares
CY2022	uncy	Weighted Average Exercise Price Options Exercised WeightedAverageExercisePriceOptionsExercised	0.45
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1342670	shares
CY2022Q4	uncy	Weighted Average Exercises Price Outstanding Ending WeightedAverageExercisesPriceOutstandingEnding	2.75
CY2022	uncy	Sharebased Compensation Arrangement By Sharebased Payments Award Options Exercisable Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentsAwardOptionsExercisableWeightedAverageRemainingContractualTerm2	P8Y5M19D
CY2022Q4	uncy	Aggregate Intrinsic Value Outstanding Ending AggregateIntrinsicValueOutstandingEnding	52000	usd
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.86
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	683661	shares
CY2022	uncy	Weighted Exercise Price Option Vested And Exercisable WeightedExercisePriceOptionVestedAndExercisable	3.14
CY2022	uncy	Share Based Weighted Average Remaining Contractual Term Shares Vested And Exercisable Share-basedWeightedAverageRemainingContractualTermSharesVestedAndExercisable	P7Y10M13D
CY2022	uncy	Aggregate Intrinsic Value Options Vested And Exercisable AggregateIntrinsicValueOptionsVestedAndExercisable	52000	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Number Of Shares Period Increase Decrease SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease	1100000	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y3M18D
CY2021	uncy	Exercised Stock Option ExercisedStockOption	383721	shares
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	119000	usd
CY2022Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	9546	shares
CY2022	uncy	Unvested Options Amount UnvestedOptionsAmount	31000	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	29000	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	374168	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	10000	shares
CY2022Q2	us-gaap	Restricted Stock Expense RestrictedStockExpense	7200	usd
CY2022Q2	us-gaap	Option Contract Indexed To Equity Settlement Share Fair Value Per Share OptionContractIndexedToEquitySettlementShareFairValuePerShare	0.72
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	5000	usd
CY2021Q3	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	26738	shares
CY2021Q3	us-gaap	Restricted Stock Expense RestrictedStockExpense	100000	usd
CY2021Q3	us-gaap	Option Contract Indexed To Equity Settlement Share Fair Value Per Share OptionContractIndexedToEquitySettlementShareFairValuePerShare	3.74
CY2021	uncy	Research And Development ResearchAndDevelopment	721000	usd
CY2022	uncy	Research And Development ResearchAndDevelopment	664000	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	245000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	383000	usd
CY2021	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	966000	usd
CY2022	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	1047000	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	0.21	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0239	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1627	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2404	pure
CY2021	uncy	Interest On Convertible Notes InterestOnConvertibleNotes	-0.0222	pure
CY2021	uncy	Others Others	-0.0251	pure
CY2022	uncy	Others Others	0.0065	pure
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	226000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	373000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2257000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	4156000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	468000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	428000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	2221000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	135000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	260000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	3086000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	7438000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3086000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	7438000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	4400000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements Other EffectiveIncomeTaxRateReconciliationTaxSettlementsOther	0.154	pure
CY2022	uncy	Future Taxable Income FutureTaxableIncome	13100000	usd
CY2022	uncy	Taxable Income Percentage TaxableIncomePercentage	0.80	pure
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment	444000	usd
CY2022	uncy	Reduce Future Taxable Income ReduceFutureTaxableIncome	245000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Repatriation Foreign Earnings Jobs Creation Act Of2004 EffectiveIncomeTaxRateReconciliationRepatriationForeignEarningsJobsCreationActOf2004	1	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.50	pure
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	29000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	101000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	72000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	589000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	101000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	690000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	101000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	690000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10017000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-18058000	usd
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11675750	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15057049	shares
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.86
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.2
CY2021	uncy	Options To Purchase Common Stock OptionsToPurchaseCommonStock	1211068	shares
CY2022	uncy	Options To Purchase Common Stock OptionsToPurchaseCommonStock	1342670	shares
CY2021	uncy	Warrants To Purchase Common Stock WarrantsToPurchaseCommonStock	4784193	shares
CY2022	uncy	Warrants To Purchase Common Stock WarrantsToPurchaseCommonStock	4784193	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5995261	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6126863	shares
CY2022	uncy	Aggregate Percentage AggregatePercentage	0.75	pure
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2021	us-gaap	Revenues Revenues		usd
CY2022	uncy	Loss On Debt Conversion LossOnDebtConversion		usd
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15057049	shares
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
CY2021	us-gaap	Other Noncash Expense OtherNoncashExpense		usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
CY2022	us-gaap	Paid In Kind Interest PaidInKindInterest		usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022	uncy	Deferred Compensation To Ceo DeferredCompensationToCEO		usd
CY2022	uncy	Loss On Debt Conversion LossOnDebtConversion		usd
CY2022	uncy	Related Party Service Fee Payable RelatedPartyServiceFeePayable		usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2021	uncy	Issuance Of Common Stock For Cash Net Of Issuance Costs IssuanceOfCommonStockForCashNetOfIssuanceCosts		usd
CY2022	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt		usd
CY2022	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt		usd
CY2022	us-gaap	Repayments Of Other Short Term Debt RepaymentsOfOtherShortTermDebt		usd
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments		usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents		usd
CY2021	uncy	Deferred Insurance Charges Included In Prepaid Expenses And Other Current Assets DeferredInsuranceChargesIncludedInPrepaidExpensesAndOtherCurrentAssets		usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue		usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2022	uncy	Weighted Average Remaining Contractual Termin Years Warrants Granted WeightedAverageRemainingContractualTerminYearsWarrantsGranted
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue		usd
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022	uncy	Weighted Average Remaining Contractual Termin Years Warrants Exercised WeightedAverageRemainingContractualTerminYearsWarrantsExercised
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue		usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue		usd
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes		pure
CY2022	uncy	Interest On Convertible Notes InterestOnConvertibleNotes		pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2021Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts		usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11675750	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15057049	shares
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.86
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.20
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001766140

Files In Submission

Name	View Source	Status
uncy-20221231_def.xml	Edgar Link	unprocessable
0001213900-23-024901-index-headers.html	Edgar Link	pending
0001213900-23-024901-index.html	Edgar Link	pending
0001213900-23-024901.txt	Edgar Link	pending
0001213900-23-024901-xbrl.zip	Edgar Link	pending
f10k2022ex23-1_unicycive.htm	Edgar Link	pending
f10k2022ex31-1_unicycive.htm	Edgar Link	pending
f10k2022ex31-2_unicycive.htm	Edgar Link	pending
f10k2022ex32-1_unicycive.htm	Edgar Link	pending
f10k2022ex32-2_unicycive.htm	Edgar Link	pending
f10k2022_unicycive.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
image_006.jpg	Edgar Link	pending
image_007.jpg	Edgar Link	pending
image_008.jpg	Edgar Link	pending
image_009.jpg	Edgar Link	pending
image_010.jpg	Edgar Link	pending
image_011.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
f10k2022_unicycive_htm.xml	Edgar Link	completed
image_012.jpg	Edgar Link	pending
image_013.jpg	Edgar Link	pending
image_014.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
uncy-20221231.xsd	Edgar Link	pending
uncy-20221231_lab.xml	Edgar Link	unprocessable
uncy-20221231_cal.xml	Edgar Link	unprocessable
uncy-20221231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$UNCY
Unicycive Therapeutics, Inc. Stock $uncy

2023 Q1 Form 10-K Financial Statement

#000121390023024901 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$UNCY Unicycive Therapeutics, Inc. Stock $uncy

2023 Q1 Form 10-K Financial Statement

#000121390023024901 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$UNCY
Unicycive Therapeutics, Inc. Stock $uncy